Biocon is currently trading at Rs. 372.90, up by 12.25 points or 3.40% from its previous closing of Rs. 360.65 on the BSE.
The scrip opened at Rs. 370.50 and has touched a high and low of Rs. 377.75 and Rs. 364.40 respectively. So far 340273 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 395.65 on 17-Sep-2024 and a 52 week low of Rs. 244.40 on 20-Mar-2024.
Last one week high and low of the scrip stood at Rs. 389.00 and Rs. 356.50 respectively. The current market cap of the company is Rs. 44716.35 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 20.37% and 18.99% respectively.
The U.S. Food and Drug Administration (USFDA) has classified Biocon’s subsidiary -- Biocon Biologics’ Insulins facilities in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI). This relates to the cGMP inspection conducted by the agency between September 15 - 27, 2024. The inspection scope had included several biologics manufacturing units comprising one Drug Substance and one Drug Product manufacturing units, one Medical Device Assembly unit, one Analytical Quality Control Laboratory, two Microbiological Control Laboratories and two Warehouses.
Biocon Biologics remains committed to global standards of Quality and Compliance.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: